Nexplanon® [Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD), UK] is a progestogen-only subdermal implant that has now replaced the contraceptive implant, Implanon®. Nexplanon and Implanon are bioequivalent (i.e. they both contain 68 mg etonogestrel and they have the same release rate and 3-year duration of action). The main differences are that Nexplanon is radio-opaque and has a different application device and insertion technique.
This document is not current and may have been updated